Recent clinical evidence suggests a significant association between SGLT2 inhibitors stroke risk reduction in high-risk diabetic populations. Specifically, patients with type 2 diabetes (T2D) and diabetic retinopathy (DR) face a heightened threat of cerebrovascular events. This multicenter study explored whether sodium-glucose cotransporter-2 inhibitors (SGLT2i) could effectively mitigate these risks. Researchers compared SGLT2i users against those taking metformin or DPP-4 inhibitors using TriNetX data.

Impact of SGLT2 Inhibitors Stroke Risk Reduction

After meticulous matching, the results revealed substantial benefits for SGLT2i users. Notably, the risk of hemorrhagic stroke (HS) decreased by 24% within one year. This protective effect remained consistently lower throughout the five-year follow-up period. Furthermore, the risk of ischemic stroke (IS) showed a significant 8% reduction by the fifth year.

Subgroup analyses provided even more granular insights into patient outcomes. Patients with early-stage retinopathy and an HbA1c below 7% experienced the most pronounced benefits. Moreover, the study demonstrated consistent risk reductions in patients with neuropathy and chronic kidney disease. These findings highlight SGLT2 inhibitors as a versatile tool for managing macrovascular complications beyond glycemic control.

In conclusion, SGLT2 inhibitors offer significant cerebrovascular protection to patients with T2D and DR. While these retrospective findings are promising, clinicians should await prospective trials. Nevertheless, low numbers needed to treat suggest SGLT2i could be pivotal for diabetic care in India.

Frequently Asked Questions

How do SGLT2 inhibitors specifically affect stroke subtypes?

The study found that SGLT2 inhibitors provide a faster and more significant reduction in hemorrhagic stroke risk compared to ischemic stroke. While HS risk decreased within the first year, IS risk reduction became statistically significant at the five-year follow-up mark.

Are these benefits consistent across all diabetic patients?

The research specifically focused on patients with diabetic retinopathy. However, sensitivity analyses confirmed that the protective benefits for hemorrhagic stroke remained consistent in patients with comorbid conditions like neuropathy, nephropathy, and chronic kidney disease.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Chen KE et al. Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study. Diabetes Obes Metab. 2026 Apr 13. doi: 10.1111/dom.70744. PMID: 41969190.

Yen FS et al. SGLT2 Inhibitors and the Risk of Sight-Threatening Retinopathy in Patients With Type 2 Diabetes. JAMA Netw Open. 2023 Dec 20. doi: 10.1001/jamanetworkopen.2023.48440.

Wong KH et al. Diabetic Retinopathy and Risk of Stroke: A Secondary Analysis of the ACCORD Eye Study. Stroke. 2020 Feb. doi: 10.1161/STROKEAHA.119.027961.